These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 9264480)
1. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Chandler WL; Alessi MC; Aillaud MF; Henderson P; Vague P; Juhan-Vague I Circulation; 1997 Aug; 96(3):761-8. PubMed ID: 9264480 [TBL] [Abstract][Full Text] [Related]
2. The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Chandler WL; Levy WC; Stratton JR Circulation; 1995 Nov; 92(10):2984-94. PubMed ID: 7586269 [TBL] [Abstract][Full Text] [Related]
4. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795 [TBL] [Abstract][Full Text] [Related]
5. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop. Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954 [TBL] [Abstract][Full Text] [Related]
6. Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis. Opatrný K; Opatrná S; Vít L; Opatrný K Am J Nephrol; 1998; 18(3):186-92. PubMed ID: 9627033 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; Bolt-De Vries J; Benraad TJ; Foekens JA Br J Cancer; 1999 Apr; 80(1-2):286-94. PubMed ID: 10390010 [TBL] [Abstract][Full Text] [Related]
8. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238 [TBL] [Abstract][Full Text] [Related]
9. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells. Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258 [TBL] [Abstract][Full Text] [Related]
10. A kinetic model of the circulatory regulation of tissue plasminogen activator. Chandler WL Thromb Haemost; 1991 Sep; 66(3):321-8. PubMed ID: 1746003 [TBL] [Abstract][Full Text] [Related]
12. Tissue plasminogen activator and plasminogen activator inhibitors of type 1 and type 2 in the plasma of parturient women. Uszyński M; Uszyński W; Zekanowska E; Garbacz J; Kielkowski A; Marcinkowski Z J Perinat Med; 1996; 24(4):339-45. PubMed ID: 8880631 [TBL] [Abstract][Full Text] [Related]
13. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. van Leeuwen RT; Kol A; Andreotti F; Kluft C; Maseri A; Sperti G Circulation; 1994 Jul; 90(1):362-8. PubMed ID: 8026020 [TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Zhu Y; Carmeliet P; Fay WP Circulation; 1999 Jun; 99(23):3050-5. PubMed ID: 10368124 [TBL] [Abstract][Full Text] [Related]
15. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Johansson L; Jansson JH; Boman K; Nilsson TK; Stegmayr B; Hallmans G Stroke; 2000 Jan; 31(1):26-32. PubMed ID: 10625711 [TBL] [Abstract][Full Text] [Related]
16. Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Bosnyak Z; Forrest KY; Maser RE; Becker D; Orchard TJ; Diabet Med; 2003 Feb; 20(2):147-51. PubMed ID: 12581266 [TBL] [Abstract][Full Text] [Related]
17. Modulation of tissue-type plasminogen activator by retinoids in rat plasma and tissues. Van Bennekum AM; Emeis JJ; Kooistra T; Hendriks HF Am J Physiol; 1993 May; 264(5 Pt 2):R931-7. PubMed ID: 8498603 [TBL] [Abstract][Full Text] [Related]
18. [Tissue-type plasminogen activator (T-PA) and plasminogen activator inhibitor (PAI-1) in human follicular fluid during gonadotropin-induced ovulation]. Szymański W; Walentowicz M; Kotschy M Ginekol Pol; 2003 Oct; 74(10):1386-91. PubMed ID: 14669449 [TBL] [Abstract][Full Text] [Related]
19. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression. Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076 [TBL] [Abstract][Full Text] [Related]
20. Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator. Björquist P; Ehnebom J; Inghardt T; Deinum J Biochim Biophys Acta; 1997 Aug; 1341(1):87-98. PubMed ID: 9300812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]